IngredientesLa albúmina, frecuentemente referida en textos históricos como "albuminis," es una proteína vital comúnmente obtenida de claras de huevo, leche y suero sanguíneo. Su uso medicinal se remonta a siglos atrás, con practicantes que reconocían sus notables propiedades nutricionales y restauradoras. En los siglos XIX y principios del XX, la albúmina era un pilar en los remedios para la convalecencia. Los médicos prescribían albúmina de clara de huevo en bebidas o caldos a pacientes debilitados por enfermedades o cirugías, apreciando su fácil digestibilidad y su rico contenido de aminoácidos. Esta práctica ayudaba a apoyar la recuperación al suministrar los componentes esenciales para la reparación de tejidos y la función inmune.
Más allá de su uso individual, la albúmina frecuentemente figuraba en combinaciones herbales tradicionales, especialmente en la medicina popular europea y asiática. Los herbolarios mezclaban alimentos ricos en albúmina con plantas botánicas como la raíz de regaliz, el ginseng o la raíz de malvavisco para potenciar sus efectos nutricionales y calmantes. Se creía que estas combinaciones fortalecían la sangre, nutrían el cuerpo y ayudaban a quienes sufrían de fatiga crónica o enfermedades debilitantes. El efecto sinérgico de la albúmina con las hierbas proporcionaba un remedio equilibrado, combinando una nutrición rápida con los beneficios holísticos de las plantas medicinales.
La ciencia nutricional moderna continúa validando la reputación histórica de la albúmina, destacando su papel fundamental en el apoyo al mantenimiento muscular, la salud inmune y la vitalidad general. Su adaptabilidad tanto en preparaciones individuales como herbales subraya su valor perdurable. El uso histórico y continuo de la albúmina en contextos nutricionales y medicinales refleja su profunda contribución a la salud y el bienestar a través de culturas y épocas.
La albúmina, frecuentemente referida como "albuminis" en ciertos contextos, es una proteína soluble en agua con alto valor nutricional y funcional, comúnmente derivada de claras de huevo o plasma sanguíneo. Su uso en productos nutricionales se remonta a principios del siglo XX, cuando fue reconocida por su capacidad para apoyar el crecimiento y la reparación de tejidos debido a su perfil completo de aminoácidos. Históricamente, la albúmina ha sido incorporada en las dietas para abordar deficiencias de proteínas, particularmente en entornos clínicos que involucran desnutrición, cicatrización de heridas y recuperación posquirúrgica.
Científicamente, la albúmina es valorada por su alto valor biológico y digestibilidad. Estudios clínicos han demostrado que la suplementación con albúmina puede mejorar el estado proteico en pacientes con hipoalbuminemia, una condición frecuentemente observada en enfermedades crónicas o lesiones graves. Por ejemplo, la albúmina intravenosa se administra frecuentemente en hospitales para apoyar la presión oncótica y facilitar el equilibrio de líquidos, aunque esto es distinto de la albúmina dietética. Como ingrediente dietético, la albúmina contribuye al mantenimiento muscular, la función inmune y la saciedad, lo que la convierte en una adición atractiva a los productos nutricionales diseñados para atletas, personas mayores e individuos con mayores necesidades de proteínas.
A pesar de estos beneficios, los efectos directos de la suplementación con albúmina en la población general siguen siendo un área de investigación activa. Si bien su seguridad y adecuación nutricional están bien establecidas, se necesitan ensayos clínicos más amplios y a largo plazo para demostrar definitivamente su eficacia en la prevención de enfermedades o la mejora del rendimiento. No obstante, la albúmina sigue siendo una valiosa fuente de proteínas en formulaciones nutricionales, apreciada por su versatilidad, alta calidad y su impacto favorable en la ingesta de proteínas.
Condiciones de salud que aceite de krill puede ayudar a apoyar.
Krill oil is a dietary source of astaxanthin, a carotenoid antioxidant that quenches lipid peroxyl radicals within cell membranes and scavenges aqueous radicals at membrane interfaces. Human RCTs have shown krill oil raises the omega-3 index and reduces markers of oxidative stress. Astaxanthin in krill oil has documented antioxidant activity superior to many common antioxidants in vitro.
The same 2025 RCT in MDD patients that showed antidepressant effects also found that anxiety and distress scores on the DASS-21 scale decreased significantly in the krill oil group compared to baseline (p<0.001). Animal data in senescence-accelerated mice show krill oil reduces anxiety-like behavior. Evidence is preliminary and largely co-reported with depression outcomes.
Krill oil provides EPA and DHA in phospholipid form (superior bioavailability compared to triglyceride form in fish oil) plus astaxanthin, an antioxidant that protects these fatty acids. Clinical studies show krill oil reduces triglycerides, improves endothelial function, and reduces inflammatory markers. Multiple RCTs confirm its cardiovascular lipid-modifying benefits.
Krill oil from Antarctic krill (Euphausia superba) provides omega-3 fatty acids (EPA and DHA) in phospholipid form, along with astaxanthin. The Arthritis Foundation identifies krill oil as having potential to reduce body inflammation. Preclinical OA models show cartilage protection, and it is the subject of an ongoing Australian multicenter RCT (KARAOKE trial) specifically for knee OA with synovitis.
An open-label pilot trial by Aker BioMarine in 18 boys (ages 7–11) with ADHD found improvements in EEG scores after 13 weeks of krill oil supplementation. Broader omega-3 PUFA RCTs show modest improvements in ADHD symptoms in children; krill-specific RCT evidence is limited but supported by DHA's documented role in prefrontal cortex function.
A 2025 RCT in MDD adults found krill oil supplementation significantly reduced HbA1c compared to baseline, an effect not observed with fish oil or placebo. An independent RCT also reported a significant decrease in fasting blood glucose in the krill group. A 2023 updated meta-analysis of cardiovascular RCTs found no significant overall effect on blood glucose across trials, indicating results are mixed.
Krill oil provides omega-3 fatty acids (EPA and DHA) in phospholipid form with superior bioavailability compared to fish oil, plus the antioxidant astaxanthin. A randomized, double-blind, placebo-controlled trial (Deutsch, J Am Coll Nutr 2007, n=90) found krill oil 300 mg/day for 30 days significantly reduced WOMAC pain, stiffness, and functional impairment scores and serum CRP versus placebo in OA and RA patients. A 2022 network meta-analysis identified krill oil as improving the joint microenvironment in knee OA.
Krill oil provides EPA and DHA in phospholipid form, which may enhance bioavailability versus fish oil triglycerides. It suppresses total cholesterol, LDL-C, and HMG-CoA reductase activity in animal studies, and is recognized in dyslipidemia supplement reviews for triglyceride and total cholesterol modulation.
Krill oil contains EPA and DHA bound to phospholipids, plus the antioxidant astaxanthin, giving it documented anti-inflammatory activity. Multiple randomized controlled trials and a 2026 meta-analysis confirm reductions in CRP and pro-inflammatory cytokines. Evidence is strongest for conditions driven by chronic low-grade inflammation (osteoarthritis, cardiovascular risk, IBD), though effect sizes are modest and larger confirmatory trials are still needed.
Krill oil provides phospholipid-bound EPA and DHA omega-3 fatty acids with superior bioavailability compared to fish oil triglycerides, plus astaxanthin. Clinical trials show krill oil reduces chronic low-back pain and OA joint pain. Phospholipid omega-3s reduce inflammatory markers (CRP, IL-6) relevant to chronic pain.
A 2013 RCT (Konagai et al.; n=45 healthy elderly) found krill oil improved working memory and prefrontal cortex activation versus placebo. No dedicated human clinical trials testing krill oil for prevention of cognitive decline or dementia have been conducted. Multiple animal models confirm krill oil attenuates Alzheimer's-like pathology and aging-related cognitive impairment.
A 2025 double-blind RCT (n=57 MDD adults, 8 weeks) found krill oil (520 mg EPA+DHA/day) significantly reduced Hamilton Depression Rating Scale scores versus placebo (p<0.001). Animal studies in chronic stress models show krill oil preserves brain DHA and attenuates depression-like behavior. Evidence parallels broader omega-3 PUFA literature but is limited in volume of krill-specific human trials.
A double-blind, placebo-controlled RCT (Deinema et al., Ophthalmology 2017; n=60) showed krill oil supplementation for 90 days significantly reduced tear osmolarity and OSDI symptom scores versus placebo, with the krill oil group uniquely achieving significant reductions in the proinflammatory cytokine IL-17A. These benefits were superior to or additive versus fish oil on symptom measures.
Two 2024 randomized, double-blind, placebo-controlled pilot studies (Handeland et al., PMID 39169540; n=51 and n=50 healthy adults) found that 1 g and 2 g of krill oil/day for 12 weeks produced significant, dose-dependent reductions in transepidermal water loss (TEWL) and improvements in skin hydration compared to placebo. Effects correlated linearly with increases in the omega-3 index.
Krill oil provides EPA and DHA in phospholipid form alongside astaxanthin, with anti-inflammatory properties relevant to joint health. A 6-month multicenter double-blind placebo-controlled RCT (PMC9437987) found krill oil resulted in modest but significant improvements in knee OA pain, stiffness, and physical function. A 2025 network meta-analysis (39 RCTs, 4,599 KOA patients) ranked krill oil among supplements showing potential for function improvement.
Krill oil provides EPA and DHA in phospholipid form for superior brain bioavailability compared to fish oil triglycerides, plus the potent antioxidant astaxanthin. Multiple RCTs demonstrate krill oil improves omega-3 index, reduces inflammatory markers, and supports cardiovascular and cognitive health in aging adults with superior dose efficiency.
A 2017 meta-analysis of 7 RCTs (n=662) found krill oil significantly reduced LDL cholesterol (−15.52 mg/dL) and triglycerides (−14.03 mg/dL) and raised HDL cholesterol (+6.65 mg/dL). A 2023 updated meta-analysis of 14 RCTs (n=1,458) confirmed significant reductions in total cholesterol, LDL, and triglycerides. Blood pressure was not significantly affected across trials.
In vitro studies show krill oil dose-dependently reduces LPS-induced IL-1β and TNFα in human macrophages via NF-κB pathway suppression. Animal UC models show krill oil attenuates colonic inflammation and oxidative stress. A 2024 PMC systematic review concluded krill oil has potential therapeutic benefits in IBD prevention, though no human clinical trials in IBD patients have been published.
An RCT (Konagai et al., Clinical Interventions in Aging 2013; n=45 healthy elderly) found krill oil supplementation improved working memory performance versus sardine oil and placebo, with significant prefrontal oxyhemoglobin changes detected by fNIRS. Multiple animal models show krill oil attenuates memory impairment in aging and Alzheimer's models.
A double-blind RCT (Sampalis et al., 2003; n=70 women with PMS/dysmenorrhea) found Neptune Krill Oil (2 g/day for 3 months) significantly reduced dysmenorrhea pain and analgesic use, with effects superior to fish oil. The proposed mechanism is EPA-mediated reduction of pro-inflammatory prostaglandins that cause uterine cramping.
Krill oil, rich in phospholipid-bound EPA and DHA plus the antioxidant astaxanthin, has been studied in clinical trials and meta-analyses for its effects on dyslipidemia—a core component of metabolic syndrome. A 2017 meta-analysis of 7 RCTs (662 participants) found significant reductions in LDL-C and triglycerides and a significant increase in HDL-C. However, a 2023 updated systematic review found no clinically meaningful effect of krill oil on blood pressure, fasting glucose, insulin resistance, BMI, or inflammatory markers, limiting its demonstrated benefit to the lipid profile component of metabolic syndrome rather than the syndrome as a whole.
Krill oil provides EPA and DHA in phospholipid form (with astaxanthin) and has been studied for supporting exercise recovery in athletes. An observational study cited in a 2022 PMC narrative review found krill oil supplementation supported HS-Omega-3 index recovery and post-exercise free radical scavenging after high-power training.
The Sampalis et al. (2003) double-blind RCT (n=70 women) found Neptune Krill Oil significantly improved both physical and emotional symptoms of PMS versus baseline, with improvements greater than the fish oil comparator. A 3-month pilot with 29 women using a krill oil-based formulation also showed significant reductions in PMS symptoms.
Krill oil provides omega-3 fatty acids (EPA and DHA) in phospholipid form with higher bioavailability than standard fish oil, plus astaxanthin, an antioxidant. Animal studies show it reduces arthritis scores in collagen-induced arthritis models, and a clinical study (Deutsch) found it reduced CRP and subjective symptoms in RA and OA patients.
Two 2024 randomized double-blind placebo-controlled pilot studies (Handeland et al., PMID 39169540; n=51 and n=50) found krill oil supplementation at 1–2 g/day for 12 weeks produced dose-dependent improvements in skin elasticity. Preclinical studies show krill oil upregulates collagen and hyaluronic acid synthesis genes in mouse skin.
Krill oil delivers EPA and DHA in phospholipid form, which may offer enhanced bioavailability compared to standard fish oil. Clinical studies and a systematic review/meta-analysis support its ability to reduce plasma triglycerides in humans, consistent with the known omega-3 triglyceride-lowering mechanism.
Sistemas corporales que aceite de krill puede ayudar a apoyar.
Volver